Kaia Agarwal - Hillevax VP Affairs
| HLVX Stock | USD 1.91 0.03 1.55% |
Insider
Kaia Agarwal is VP Affairs of Hillevax
| Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
| Phone | 617 213 5054 |
| Web | https://www.hillevax.com |
Hillevax Management Efficiency
The company has return on total asset (ROA) of (0.289) % which means that it has lost $0.289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6224) %, meaning that it created substantial loss on money invested by shareholders. Hillevax's management efficiency ratios could be used to measure how well Hillevax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.38 in 2024. Return On Capital Employed is likely to rise to -0.4 in 2024. At this time, Hillevax's Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 2 M in 2024, whereas Total Assets are likely to drop slightly above 173.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Saurabh MD | Centessa Pharmaceuticals PLC | 48 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| MBA MD | Entrada Therapeutics | 49 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Kyle Breidenstine | PepGen | N/A | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Karla MacDonald | Entrada Therapeutics | N/A | |
| Michael Diem | Century Therapeutics | 53 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| CPA MBA | Pharvaris BV | 63 | |
| Jennifer Cormier | PepGen | N/A | |
| Thomas Templeman | Centessa Pharmaceuticals PLC | 64 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| Luis Borges | Century Therapeutics | 62 | |
| Annie MBA | Sutro Biopharma | N/A | |
| Alan Russell | Edgewise Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.29 |
Hillevax Leadership Team
Elected by the shareholders, the Hillevax's board of directors comprises two types of representatives: Hillevax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hillevax. The board's role is to monitor Hillevax's management team and ensure that shareholders' interests are well served. Hillevax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hillevax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anju Chatterji, VP Operations | ||
| Kaia Agarwal, VP Affairs | ||
| Astrid MD, Chief Officer | ||
| Shane Maltbie, CFO Treasurer | ||
| Sean McLoughlin, Chief Officer | ||
| Paul JD, Secretary Counsel | ||
| Ozzie Berger, Senior Affairs | ||
| David Socks, Chief Officer | ||
| Aditya Kohli, Chief CoFounder |
Hillevax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hillevax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (69.21 M) | ||||
| Shares Outstanding | 49.81 M | ||||
| Shares Owned By Insiders | 17.11 % | ||||
| Shares Owned By Institutions | 75.29 % | ||||
| Number Of Shares Shorted | 1.18 M | ||||
| Price To Book | 0.52 X | ||||
| EBITDA | (132.47 M) | ||||
| Net Income | (123.57 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hillevax Stock Analysis
When running Hillevax's price analysis, check to measure Hillevax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hillevax is operating at the current time. Most of Hillevax's value examination focuses on studying past and present price action to predict the probability of Hillevax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hillevax's price. Additionally, you may evaluate how the addition of Hillevax to your portfolios can decrease your overall portfolio volatility.